Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Nunn

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 18, 2003
Bactericidal activity of antituberculosis drugsCaroline J Doré, Andrew J Nunn
Best Practice & Research. Clinical Obstetrics & Gynaecology|February 7, 2012
Statistical and methodological issues in microbicide trial designAngela M Crook, Andrew J Nunn
American Journal of Respiratory and Critical Care Medicine|March 23, 2023
Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?Carole D Mitnick, Andrew J Nunn
The Lancet. Infectious Diseases|October 30, 2016
Efficacy and safety of regimens for drug-resistant tuberculosisTom A Yates, Andrew J Nunn
Future Medicinal Chemistry|March 24, 2011
Challenges of Phase III study design for trials of new drug regimens for the treatment of TBPatrick P J Phillips, Andrew J Nunn
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2013
An analysis with serious flawsAndrew J Nunn, Patrick P J Phillips
The New England Journal of Medicine|September 12, 2019
A Shorter Regimen for Rifampin-Resistant Tuberculosis. ReplyAndrew J Nunn, Patrick P J Phillips
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 14, 2015
Reducing relapse in tuberculosis treatmentAndrew J Nunn, Patrick P J Phillips, Ibrahim Abubakar
The Journal of Investigative Dermatology|May 13, 2015
What is a pragmatic clinical trial?Hywel C Williams, Esther Burden-Teh, Andrew J Nunn
Plos One|May 14, 2013
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapsePatrick P J Phillips, Katherine Fielding, Andrew J Nunn
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
American Journal of Respiratory and Critical Care Medicine|February 18, 2003
Bactericidal activity of antituberculosis drugsCaroline J Doré, Andrew J Nunn
Best Practice & Research. Clinical Obstetrics & Gynaecology|February 7, 2012
Statistical and methodological issues in microbicide trial designAngela M Crook, Andrew J Nunn
American Journal of Respiratory and Critical Care Medicine|March 23, 2023
Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?Carole D Mitnick, Andrew J Nunn
The Lancet. Infectious Diseases|October 30, 2016
Efficacy and safety of regimens for drug-resistant tuberculosisTom A Yates, Andrew J Nunn
Future Medicinal Chemistry|March 24, 2011
Challenges of Phase III study design for trials of new drug regimens for the treatment of TBPatrick P J Phillips, Andrew J Nunn
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2013
An analysis with serious flawsAndrew J Nunn, Patrick P J Phillips
The New England Journal of Medicine|September 12, 2019
A Shorter Regimen for Rifampin-Resistant Tuberculosis. ReplyAndrew J Nunn, Patrick P J Phillips
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 14, 2015
Reducing relapse in tuberculosis treatmentAndrew J Nunn, Patrick P J Phillips, Ibrahim Abubakar
The Journal of Investigative Dermatology|May 13, 2015
What is a pragmatic clinical trial?Hywel C Williams, Esther Burden-Teh, Andrew J Nunn
Plos One|May 14, 2013
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapsePatrick P J Phillips, Katherine Fielding, Andrew J Nunn
Pageof 8